JP7617027B2 - ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 - Google Patents

ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 Download PDF

Info

Publication number
JP7617027B2
JP7617027B2 JP2021565875A JP2021565875A JP7617027B2 JP 7617027 B2 JP7617027 B2 JP 7617027B2 JP 2021565875 A JP2021565875 A JP 2021565875A JP 2021565875 A JP2021565875 A JP 2021565875A JP 7617027 B2 JP7617027 B2 JP 7617027B2
Authority
JP
Japan
Prior art keywords
human
protein
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021565875A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020229553A5 (https=
JP2022532534A5 (https=
JP2022532534A (ja
Inventor
ジェームズ ジョナサン フィンレー，ウィリアム
Original Assignee
センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by センテッサ ファーマシューティカルズ （ユーケー） リミテッド filed Critical センテッサ ファーマシューティカルズ （ユーケー） リミテッド
Publication of JP2022532534A publication Critical patent/JP2022532534A/ja
Publication of JPWO2020229553A5 publication Critical patent/JPWO2020229553A5/ja
Publication of JP2022532534A5 publication Critical patent/JP2022532534A5/ja
Priority to JP2025001728A priority Critical patent/JP2025039660A/ja
Application granted granted Critical
Publication of JP7617027B2 publication Critical patent/JP7617027B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021565875A 2019-05-13 2020-05-13 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用 Active JP7617027B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025001728A JP2025039660A (ja) 2019-05-13 2025-01-06 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB1906685.1A GB201906685D0 (en) 2019-05-13 2019-05-13 Activatable protein constructs and uses thereof
GB1906685.1 2019-05-13
GBGB1910254.0A GB201910254D0 (en) 2019-05-13 2019-07-17 Activatable protein constructs and uses thereof
GB1910254.0 2019-07-17
GBGB1917678.3A GB201917678D0 (en) 2019-05-13 2019-12-04 Activatable protein constructs and uses thereof
GB1917678.3 2019-12-04
GBGB2001196.1A GB202001196D0 (en) 2019-05-13 2020-01-28 Activatable protein constructs and uses thereof
GB2001196.1 2020-01-28
PCT/EP2020/063362 WO2020229553A1 (en) 2019-05-13 2020-05-13 Activatable bispecific antibodies comprising a linker between the two binding domains which is a human immunoglobulin hinge region, or a variant thereof, and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025001728A Division JP2025039660A (ja) 2019-05-13 2025-01-06 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用

Publications (4)

Publication Number Publication Date
JP2022532534A JP2022532534A (ja) 2022-07-15
JPWO2020229553A5 JPWO2020229553A5 (https=) 2023-05-22
JP2022532534A5 JP2022532534A5 (https=) 2023-05-22
JP7617027B2 true JP7617027B2 (ja) 2025-01-17

Family

ID=67384589

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021565875A Active JP7617027B2 (ja) 2019-05-13 2020-05-13 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用
JP2025001728A Pending JP2025039660A (ja) 2019-05-13 2025-01-06 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025001728A Pending JP2025039660A (ja) 2019-05-13 2025-01-06 ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用

Country Status (13)

Country Link
US (1) US20230192899A1 (https=)
EP (1) EP3969116A1 (https=)
JP (2) JP7617027B2 (https=)
KR (1) KR20220008841A (https=)
CN (2) CN113840634B (https=)
AU (1) AU2020276891A1 (https=)
BR (1) BR112021022661A2 (https=)
CA (1) CA3138827A1 (https=)
GB (4) GB201906685D0 (https=)
IL (1) IL287890A (https=)
MX (1) MX2021013844A (https=)
SG (1) SG11202112114YA (https=)
WO (1) WO2020229553A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025039660A (ja) * 2019-05-13 2025-03-21 センテッサ ファーマシューティカルズ （ユーケー） リミテッド ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
EP4034171A1 (en) * 2019-09-23 2022-08-03 Cytomx Therapeutics Inc. Anti-cd47 antibodies, activatable anti-cd47 antibodies, and methods of use thereof
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2023547499A (ja) * 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2023144423A1 (en) * 2022-01-31 2023-08-03 LockBody Therapeutics Ltd Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
CA3246893A1 (en) * 2022-03-30 2023-10-05 Centessa Pharmaceuticals (Uk) Limited Activable Bispecific Anti-CD3 and Anti-PD-L1 Proteins and Their Uses
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
CA3251998A1 (en) 2022-05-16 2023-11-23 Byondis B.V. Novel masked antibodies
GB202302074D0 (en) * 2023-02-14 2023-03-29 Creasallis Ltd Agents, methods and uses thereof
WO2024218512A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd89 and anti-pd-l1 proteins and uses thereof
WO2024218509A1 (en) * 2023-04-19 2024-10-24 Centessa Pharmaceuticals (Uk) Limited Activatable bispecific anti-cd28 and anti pd-l1 proteins and uses thereof
KR20250088543A (ko) * 2023-05-19 2025-06-17 서울대학교산학협력단 Cd3 유전자 편집된 cd3 표적 스위처블 car-t 세포
CN121866269A (zh) * 2023-09-14 2026-04-14 Abl生物公司 通过施用抗pd-l1/抗4-1bb双特异性抗体治疗癌症的方法
WO2026038050A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038047A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof
WO2026038048A2 (en) * 2024-08-14 2026-02-19 Creasallis Ltd Agents, methods and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529853A (ja) 2014-09-25 2017-10-12 アムジエン・インコーポレーテツド プロテアーゼにより活性化可能な二重特異性タンパク質

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2352763T5 (pl) * 2008-10-01 2023-01-30 Amgen Research (Munich) Gmbh Bispecyficzne przeciwciała jednołańcuchowe o specyficzności wobec antygenów docelowych o dużej masie cząsteczkowej
CA2822366A1 (en) 2010-12-23 2012-06-28 Janssen Biotech, Inc. Active protease-resistant antibody fc mutants
KR102499191B1 (ko) * 2016-03-18 2023-02-13 프레드 허친슨 캔서 센터 Cd20 면역요법을 위한 조성물 및 방법
CR20180453A (es) * 2016-03-22 2018-12-05 Hoffmann La Roche Moleculas biespecíficas de células t activadas por proteasas
AU2018250641B2 (en) * 2017-04-11 2025-03-13 Inhibrx Biosciences, Inc. Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same
EP3668897B1 (en) 2017-08-18 2024-06-05 Centessa Pharmaceuticals (UK) Limited Binding agents
GB201803892D0 (en) 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
GB201906685D0 (en) * 2019-05-13 2019-06-26 Ultrahuman Six Ltd Activatable protein constructs and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017529853A (ja) 2014-09-25 2017-10-12 アムジエン・インコーポレーテツド プロテアーゼにより活性化可能な二重特異性タンパク質

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025039660A (ja) * 2019-05-13 2025-03-21 センテッサ ファーマシューティカルズ （ユーケー） リミテッド ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用

Also Published As

Publication number Publication date
KR20220008841A (ko) 2022-01-21
GB201906685D0 (en) 2019-06-26
SG11202112114YA (en) 2021-11-29
CN113840634B (zh) 2025-07-08
EP3969116A1 (en) 2022-03-23
JP2025039660A (ja) 2025-03-21
GB201910254D0 (en) 2019-08-28
GB202001196D0 (en) 2020-03-11
JP2022532534A (ja) 2022-07-15
BR112021022661A2 (pt) 2022-03-29
CN113840634A (zh) 2021-12-24
GB201917678D0 (en) 2020-01-15
MX2021013844A (es) 2022-03-17
AU2020276891A1 (en) 2021-12-23
CN120554533A (zh) 2025-08-29
WO2020229553A1 (en) 2020-11-19
CA3138827A1 (en) 2020-11-19
IL287890A (en) 2022-01-01
US20230192899A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
JP7617027B2 (ja) ヒト免疫グロブリンヒンジ領域またはそのバリアントである２つの結合ドメイン間のリンカーを含む活性化可能な二重特異性抗体及びその使用
US12173067B2 (en) C-KIT antibodies and method for treating cancer with such
CN105980409B (zh) 靶向her2的双特异性抗原结合构建体
US10858435B2 (en) PD1 binding agents
CN107108748A (zh) SIRPα免疫球蛋白融合蛋白
WO2018213335A1 (en) Activatable antibodies and methods of use thereof
EP4110398A1 (en) Antibodies conjugated with fatty acid molecules and uses thereof
US20240124574A1 (en) Bispecific Antibodies with Charge Pairs and Uses Thereof
CA3091307A1 (en) Csf1r binding agents
US20250002585A1 (en) Activatable bispecific anti-cd47 and anti-pd-l1 proteins and uses thereof
EA048625B1 (ru) Слитые белки, содержащие пару лиганд-рецептор и биологически функциональный белок
CN117015556A (zh) 带电荷对的双特异性抗体及其应用
HK40082596A (en) Antibodies conjugated with fatty acid molecules and uses thereof
HK1229359B (en) Bispecific antigen-binding constructs targeting her2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230512

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231228

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240112

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240126

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250106

R150 Certificate of patent or registration of utility model

Ref document number: 7617027

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150